COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A32737 072396.0225	Serial No. 09/844,915
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Robbins et al.	
	Filing Date April 27, 2001	Group Art Unit ~~1633~~ 1635

RECEIVED
FEB 26 2002
TECHNOLOGY CENTER 1600/2900

PATENT & TRADEMARK OFFICE
FEB 20 2002

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENT

		Document No.	Date	Country	Class	SubClass	Translation Yes	Translation No
LL		9 5 3 5 0 3 2	12/28/95	WIPO				

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

LL		Liang et al. "Phenotype and allostimulatory function of dendritic cells treated with antisence oligonucleotides targeting CD80 or CD86 mRNA," Transplantation Proceedings, Vol. 33, No. 1-2 p. 235.
LL		Takayama et al. "Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potiently tolerogenic antigen-presenting cells", Transplantation Vol. 68, No. 12, pp.1903-1909, Dec. 1999.
LL		Thomson et al. "Are dendritic cells the key to liver transplant tolerance?" Immunology Today, Vol. 20, No. 1, pp.27-32, Jan. 1999.

Examiner Linda Pell Date Considered 11/20/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A32737 072396.0225	Serial No 09/844,915	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT **(Use several sheets if necessary)**	Applicant Robbins et al.		
	Filing Date April 27, 2001	Group Art Unit 1632 1635	

Ranieri *et al.*, " Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination,"*J. Virol.* 73:10416-10425 (1999).

Rea *et al.*, "Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset,"*J. Virol.* 73:10245-10253 (1999).

Thomson and Lu, "Dendritic cells as regulators of immune reactivity: implications for transplantation," *Transplantation* 68:1-8 (1999).

Tuting *et al.*,"Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity," *J. Gene Med.* 1:400-406 (1999).

Banchereau and Steinman, "Dendritic cells and the control of immunity," *Nature* 392:245-252 (1998).

Khanna *et al.*, " Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow," *Transplantation* 65:479-485 (1998).

Lee *et al.*,"Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta,"*Transplantation* 66:1810-1817 (1998).

Lu *et al.* *Journal of Leukocyte Biology* Supplement 2 Abstract#B52 (1998).

Rescigno *et al.*,"Dendritic cell survival and maturation are regulated by different signaling pathways," *J. Exp. Med.* 188:2175-2180 (1998).

Lu *et al.*, "Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival," *Transplantation* 64:1808-1815 (1997).

Fu *et al.*, "Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts," *Transplant Proc.* 29:1310 (1997).

Fu *et al.*, "Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients," *Transplantation* 62:659-665 (1996).

NY02 361185 1

Examiner Date Considered 11/20/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No. A32737 072396.0225	Serial No. 09/844,915
Applicant Robbins et al.	
Filing Date April 27, 2001	Group Art Unit ~~1633~~ 1635

LJ			Lu *et al.*, "Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis," *J. Immunol.* 157:3577-3586 (1996).
			Lu *et al.*," Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes," *Transplantation* 60:1539-1545 (1995).
			Rastellini *et al.*," Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival,"*Transplantation* 60:1366-1370 (1995).
			Andrews and Faller, " A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells,"*Nucleic Acids Res.* 19:2499 (1991).
			Jolly, D., "Viral vector systems for gene therapy," *Cancer Gene Therapy*, 1:51-64. (1994).
			Starzl *et al.*,"The biological basis of and strategies for clinical xenotransplantation." *Immunological Reviews* 141:213 (1994).
			Woo *et al.*, "Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells." *Transplantation* 58:848 (1994).
			Berkner, K.L., "Expression of heterologous sequences in adenoviral vectors," *Curr. Top. Micro Immunol*, 158:39-66. (1992).
			Inaba *et al.*,"Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor," *J Exp. Med.* 176:1693-1702 (1992).
			Horwitz, M.S., "Adenoviridae and Their Replication," in *Virology*, 2nd edition, Fields *et al.*, eds., Raven Press, New York, 1990
LJ			Billiar *et al.*,"An L-arginine-dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro," *J. Exp. Med.* 169:1467-1472 (1989).

NY02 361185 1

Examiner [signature] Date Considered 11/20/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.	Serial No.
A32737 072396.0225	09/844,915
Applicant: Robbins et al.	
Filing Date: April 27, 2001	Group Art Unit: 1633 1635

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

OIPE JC10
DEC 26 2001
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
[illegible]		5 8 7 1 7 2 8	2 16 99	Thomson et al.			

FOREIGN PATENT DOCUMENT

		Document No.	Date	Country	Class	SubClass	Translation Yes	No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

[illegible]			Hirano *et al.*, "Graft hyporeactivity induced by immature donor-derived dendritic cells," *Transplant Proc.* 32:260-264 (2000)
			Gao *et al.*, "CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection," *Immunology* 98 :159-170 (1999).
			Lee *et al.*, " Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B,"*Transplantation* 68:1255-1263 (1999).
			Lu *et al.*, "Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig)," *J. Leukoc. Biol.* 66:293-296 (1999)
[illegible]			Lu *et al.*, " Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients,"*Gene Ther.* 6:554-563 (1999).

Examiner [illegible] Date Considered 11/20/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant